To determine whether activation of the STING signaling pathway could enhance the antitumor efficacy of DHODH inhibitors, we first evaluated the combinatorial effects of EA6 (0.5 μM) and MSA, a well-characterized STING agonist, in A375 and B16F10 melanoma cells across varying molar ratios (Fig. 2A-B). This evidence concerns the gene STING1 and melanoma.